Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baidu
BIDU
|
+$462M |
| 2 |
AGN
Allergan plc
AGN
|
+$390M |
| 3 |
AT&T
T
|
+$371M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$353M |
| 5 |
NextEra Energy
NEE
|
+$326M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.97B |
| 2 |
Meta Platforms (Facebook)
META
|
+$435M |
| 3 |
Pfizer
PFE
|
+$377M |
| 4 |
GE Aerospace
GE
|
+$354M |
| 5 |
Starbucks
SBUX
|
+$323M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.43% |
| 2 | Technology | 12.71% |
| 3 | Consumer Staples | 9.79% |
| 4 | Financials | 8.2% |
| 5 | Utilities | 8.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2851
Esquire Financial Holdings
ESQ
$1.14B
| $412K | ﹤0.01% |
27,357
-26,043
| -49% | -$571K |
|
|
SACH
2852
Sachem Capital Corp
SACH
$40.6M
| $412K | ﹤0.01% |
236,795
-74,105
| -24% | -$274K |
|
2853
Immunic
IMUX
$191M
| $411K | ﹤0.01% |
6,793
+730
| +12% | +$58.7K |
|
|
SWTX
2854
DELISTED
SpringWorks Therapeutics
SWTX
| $410K | ﹤0.01% |
+15,200
| New | +$496K |
|
2855
Harte-Hanks
HHS
$16.8M
| $409K | ﹤0.01% |
260,341
+2,000
| +0.8% | +$5.95K |
|
|
SIFY
2856
Sify Technologies
SIFY
$1.14B
| $408K | ﹤0.01% |
90,555
+1,467
| +2% | +$9.69K |
|
|
VRS
2857
DELISTED
Verso Corporation
VRS
| $407K | ﹤0.01% |
+36,100
| New | +$563K |
|
|
BREW
2858
DELISTED
Craft Brew Alliance, Inc.
BREW
| $407K | ﹤0.01% |
+27,300
| New | +$428K |
|
2859
iShares MSCI Philippines ETF
EPHE
$145M
| $406K | ﹤0.01% |
+17,600
| New | +$521K |
|
|
IFLN
2860
Invesco Bloomberg Enhanced Fallen Angels ETF
IFLN
$306M
| $406K | ﹤0.01% |
24,500
-13,500
| -36% | -$250K |
|
|
DBD
2861
DELISTED
Diebold Nixdorf Incorporated
DBD
| $406K | ﹤0.01% |
115,281
-418,719
| -78% | -$3.55M |
|
|
FRGI
2862
DELISTED
Fiesta Restaurant Group, Inc.
FRGI
| $405K | ﹤0.01% |
100,500
-93,966
| -48% | -$821K |
|
2863
Summit Therapeutics
SMMT
$10.8B
| $401K | ﹤0.01% |
169,299
-20,535
| -11% | -$35.3K |
|
2864
J. Jill
JILL
$287M
| $400K | ﹤0.01% |
144,761
+45,438
| +46% | +$223K |
|
2865
Celcuity
CELC
$4.53B
| $399K | ﹤0.01% |
61,460
+26,160
| +74% | +$244K |
|
2866
Highway Holdings
HIHO
$5.04M
| $399K | ﹤0.01% |
196,727
+3,100
| +2% | +$6.07K |
|
2867
Sypris Solutions
SYPR
$47.7M
| $398K | ﹤0.01% |
647,097
+23,600
| +4% | +$20.4K |
|
|
FOE
2868
DELISTED
Ferro Corporation
FOE
| $398K | ﹤0.01% |
+42,500
| New | +$540K |
|
2869
Kodak
KODK
$965M
| $397K | ﹤0.01% |
229,500
+110,200
| +92% | +$331K |
|
|
TCRR
2870
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $397K | ﹤0.01% |
+51,300
| New | +$628K |
|
|
JCAP
2871
DELISTED
Jernigan Capital, Inc.
JCAP
| $397K | ﹤0.01% |
36,200
+16,000
| +79% | +$281K |
|
2872
Coca-Cola Consolidated
COKE
$12.3B
| $396K | ﹤0.01% |
+19,000
| New | +$474K |
|
|
TCON
2873
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $394K | ﹤0.01% |
11,586
+4,010
| +53% | +$233K |
|
2874
Inuvo
INUV
$18M
| $393K | ﹤0.01% |
166,337
-11,741
| -7% | -$32.8K |
|
2875
Lightpath Technologies
LPTH
$753M
| $392K | ﹤0.01% |
366,776
+17,681
| +5% | +$17.5K |
|
Similar funds
Renaissance Technologies's Q1 2020 Portfolio in Review
As of Q1 2020, Renaissance Technologies held 4,047 positions worth $103B, down 21% from $130B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Renaissance Technologies's Q1 2020 filing shows 573 new, 1,474 increased, 1,328 reduced and 645 closed positions. Its largest new stake was AT&T: 13,563,699 shares worth $299M. The largest sale was Tesla, an estimated $1.97B.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 21% a quarter earlier, followed by Technology and Consumer Staples.
- Renaissance Technologies's largest Q1 2020 buy was AT&T: 13,563,699 shares worth $299M.
- Renaissance Technologies added most to Baidu in Q1 2020, an estimated $462M increase.
- Renaissance Technologies's biggest Q1 2020 reduction was Tesla, cutting an estimated $1.97B.
- Renaissance Technologies fully exited Phillips 66 in Q1 2020, selling an estimated $214M.
- Renaissance Technologies's ten largest holdings make up 15% of its $103B portfolio in Q1 2020.
- Renaissance Technologies opened 573 new positions and closed 645 in Q1 2020.
- Renaissance Technologies's portfolio value fell 21% quarter-over-quarter to $103B.
Based on Renaissance Technologies's 13F filing for Q1 2020, filed 14 May 2020.